



FOR: CARDIOCOMM SOLUTIONS, INC.  
TSX VENTURE SYMBOL: EKG

*August 29, 2012*

## **CardioComm Solutions, Inc. Receives Health Canada Approval to Market the HeartCheck™ ECG Monitor as a Prescription Product**

### **Canadian Approval is the first of three Health Canada Applications for the HeartCheck™ Brand of Hand-Held Heart Rhythm and ECG Devices**

Toronto, Canada – August 28, 2012 - - CardioComm Solutions, Inc. (TSX-V: EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of ECG acquisition and management software solutions, has received clearance from Health Canada for the sales and marketing of their Class II medical device for prescription based, hand-held ECG monitoring under the HeartCheck™ brand.

The Health Canada licence (89556) was granted August 27, 2012. The HeartCheck™ ECG Monitor can be connected to any computer to upload recorded ECGs to CardioComm Solutions’ C4 medical call service and telemedicine group for review by the company’s physicians who will provide ECG interpretations. This ECG management and interpretation solution has been used in collaboration with the Heart and Stroke Foundation of Canada for performing arrhythmia screening and atrial fibrillation detection in 2012. Approval of the device under CardioComm Solutions’ HeartCheck™ branding opens the door for proper brand and product intellectual property protection as the Company now prepares for the over-the-counter and prescription HeartCheck™ device launches in Canada and the United States.

“We are pleased with the Health Canada approval of our license and that we are now able to promote the sale of the ECG monitor version of the hand held devices in Canada directly under our HeartCheck™ brand. We are readying for the results of the HeartCheck™ PEN license application, both the locked (unlockable) and unlocked (ECG displaying) versions which will then allow for a co-ordinated North American launch of our products and services”, said Etienne Grima, CEO of CardioComm Solutions.

In regards to the market that CardioComm Solutions is targeting, CardioComm Solutions’ board member, Simi Grosman stated, “Consumers are seeing a larger portion of healthcare costs falling back on them. The average consumer, therefore, is becoming more motivated to manage his or her health to help contain healthcare expenses and related insurance premiums. CardioComm Solutions will continue to develop and make available products like the HeartCheck™ PEN and the HeartCheck™ ECG Monitor”.

“With further device and software approvals from the FDA and Health Canada anticipated by the end of 2012, CardioComm Solutions is emphasizing that we intend to establish a successful and innovative line of ‘connected health’ products. These products will enable consumers and patients to put their heart health into their own hands and to enable easier and more cost effective telemedicine and remote monitoring solutions for prescribed services as well as for self monitoring initiatives”.

For more information on the HeartCheck™ brand of products and associated remote and home based ECG services, please go to [www.theheartcheck.com](http://www.theheartcheck.com).

#### **About CardioComm Solutions**

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North



American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Etienne Grima, Chief Executive Officer

1-877-977-9425

[egrima@cardiocommsolutions.com](mailto:egrima@cardiocommsolutions.com)

[www.cardiocommsolutions.com](http://www.cardiocommsolutions.com)

**Forward-looking statements**

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release